Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Innate Pharma (IPHA) has reported Invested Capital for 9 consecutive years, with $25.7 million the latest figure, recorded in Q4 2025.

• Quarterly Invested Capital fell 27.18% year-over-year to $25.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $132.1 million (down 21.05% YoY) and the FY2025 annual result came in at $25.7 million, down 27.18% from the prior year.
• Invested Capital declined to $25.7 million in Q4 2025 per IPHA's latest filing, from $30.8 million in the prior quarter.
• Over the last five years, Invested Capital for IPHA reached as high as $50.4 million in Q4 2021 and fell as low as $18.8 million in Q2 2021.
• A 5-year average of $39.0 million and a median of $42.9 million in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2021 — Invested Capital soared 198.47% — and 2025, when it decreased 27.18%.
• Year by year, Invested Capital stood at $50.4 million in 2021, then fell by 4.52% to $48.1 million in 2022, then retreated by 5.58% to $45.4 million in 2023, then fell by 22.3% to $35.3 million in 2024, then fell by 27.18% to $25.7 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $25.7 million, $30.8 million, and $35.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.